Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare DRUG vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Betashares Global Healthcare Currency Hedged ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

CURE

Popularity

Low

Low

Pearlers invested

79

82

Median incremental investment

$736.96

$678.72

Median investment frequency

Monthly

Monthly

Median total investment

$2,282.12

$2,196.90

Average age group

> 35

> 35

Key Summary

DRUG

CURE

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 184.38m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 46.59m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

AUD - AUSTRALIA DOLLAR (0 %)

BRL - BRAZILIAN REAL (0 %)

CHF - SWISS FRANC (0 %)

Moderna Inc (2.72 %)

Exelixis Inc (1.80 %)

Amgen Inc (1.79 %)

Top 3 industries

Other (75.91 %)

Communication Services (33.53 %)

Health Care (23.80 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (72.30 %)

Switzerland (11.31 %)

United Kingdom of Great Britain and Northern Ireland (5.57 %)

United States (96.74 %)

Switzerland (1.43 %)

United Kingdom of Great Britain and Northern Ireland (1.23 %)

Management fee

0.57 %

0.45 %

Key Summary

DRUG

CURE

Issuer

BetaShares

Global X

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.57 %

0.45 %

Price

$9.80

$75.62

Size

$192.118 million

$50.133 million

10Y return

122.73 %

N/A

Annual distribution yield (5Y)

1.82 %

0.03 %

Market

ASX

ASX

First listed date

08/08/2016

12/11/2018

Purchase fee

$6.50

$6.50

Community Stats

DRUG

CURE

Popularity

Low

Low

Pearlers invested

79

82

Median incremental investment

$736.96

$678.72

Median investment frequency

Monthly

Monthly

Median total investment

$2,282.12

$2,196.90

Average age group

> 35

> 35

Pros and Cons

DRUG

CURE

Pros

  • Higher distribution yield

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

DRUG

CURE

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield